These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 26397936)
1. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936 [No Abstract] [Full Text] [Related]
3. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468 [TBL] [Abstract][Full Text] [Related]
4. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma. Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175 [No Abstract] [Full Text] [Related]
5. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604 [TBL] [Abstract][Full Text] [Related]
6. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046 [TBL] [Abstract][Full Text] [Related]
7. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Morrison VA; Weller EA; Habermann TM; Li S; Fisher RI; Cheson BD; Peterson BA Leuk Lymphoma; 2017 Aug; 58(8):1814-1822. PubMed ID: 27967294 [TBL] [Abstract][Full Text] [Related]
8. R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Svendsen P; Shekhrajka N; Nielsen KL; Vestergaard P; Poulsen MØ; Vistisen AK; Munksgaard PS; Severinsen MT; Jensen P; Johnsen HE; Jakobsen LH; Bøgsted M; Frøkjær JB; El-Galaly TC Leuk Lymphoma; 2017 May; 58(5):1105-1113. PubMed ID: 27736260 [TBL] [Abstract][Full Text] [Related]
9. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075 [TBL] [Abstract][Full Text] [Related]
10. Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918). Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):15-6. PubMed ID: 27007007 [No Abstract] [Full Text] [Related]
11. Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients. Brito ABC; Delamain MT; de Oliveira C; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Silvia Passos Lima C Br J Haematol; 2017 May; 177(4):650-654. PubMed ID: 27098707 [No Abstract] [Full Text] [Related]
12. [Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma]. Takahashi A; Mishima Y; Yokoyama M; Inoue N; Kusano Y; Gunji T; Nitta H; Ueda K; Nishimura N; Tsuyama N; Takeuchi K; Terui Y; Hatake K Rinsho Ketsueki; 2017; 58(5):427-432. PubMed ID: 28592754 [TBL] [Abstract][Full Text] [Related]
13. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268 [TBL] [Abstract][Full Text] [Related]
14. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370 [TBL] [Abstract][Full Text] [Related]
15. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884 [TBL] [Abstract][Full Text] [Related]
16. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I Platelets; 2019; 30(5):637-645. PubMed ID: 30047815 [TBL] [Abstract][Full Text] [Related]
17. Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. Arima H; Maruoka H; Nasu K; Tabata S; Kurata M; Matsushita A; Imai Y; Takahashi T; Ishikawa T Leuk Lymphoma; 2013 Dec; 54(12):2645-53. PubMed ID: 23566159 [TBL] [Abstract][Full Text] [Related]
18. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018 [TBL] [Abstract][Full Text] [Related]
19. Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. Bozzoli V; Tisi MC; Maiolo E; Alma E; Bellesi S; D'Alo' F; Voso MT; Leone G; Hohaus S Br J Haematol; 2015 Jun; 169(6):787-94. PubMed ID: 25819007 [TBL] [Abstract][Full Text] [Related]
20. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Boslooper K; Kibbelaar R; Storm H; Veeger NJ; Hovenga S; Woolthuis G; van Rees B; de Graaf E; van Roon E; Kluin-Nelemans HC; Joosten P; Hoogendoorn M Leuk Lymphoma; 2014 Mar; 55(3):526-32. PubMed ID: 23734653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]